01—Abstract
Summary
Summary of the 10-Q filed May 6, 2025. Cited figures are marked; the original filing is the authoritative source.
International Flavors & Fragrances Inc. (IFF) reported a first-quarter 2025 net loss attributable to IFF shareholders of $1.018 billiona, or $(3.98) per share, compared with net income of $60 million, or $0.23 per share, in the prior-year period.
The loss was driven by a $1.153 billionb goodwill impairment related to the Food Ingredients reporting unit. Net sales declined 2% on a reported basis to $2.843 billion from $2.899 billion, though currency-neutral sales rose 2% and comparable currency-neutral sales rose 3%. Segment Adjusted Operating EBITDA was flat at $578 million in total, with Taste and Pharma Solutions up and Scent down.
The balance sheet shows total assets of $28.265 billionc and total debt of $9.290 billion as of March 31, 2025. Cash flow from operations was $127 million, versus $99 million a year earlier. Capital expenditures rose to $179 million from $118 million, and the company expects 2025 capital spending of approximately 6.5% of sales, up from 4.0% in 2024.
Shareholders' equity fell to $13.177 billiond from $13.876 billion, largely due to the net loss. Subsequent to quarter-end, the Pharma Solutions disposal group sale closed on May 1, 2025, with gross cash proceeds of approximately $2.6 billion, of which a portion repaid the remaining $397 million under the 2026 Term Loan Facility.
The Tobacco Flavoring business sale in North America closed April 1, 2025, for $20 million in gross proceeds, and the Nitrocellulose sale is expected to close in the second quarter of 2025. The company also announced tender offers of up to $1.8 billion for certain Senior Notes on May 2, 2025.
02—Key points
Key Highlights
- Net loss attributable to IFF shareholders of $1.018 billion, or $(3.98) per share, versus net income of $60 million, or $0.23 per share, in Q1 2024, primarily due to a $1.153 billion goodwill impairment in the Food Ingredients reporting unit.
- Net sales of $2.843 billion, down 2% on a reported basis from $2.899 billion; currency-neutral sales rose 2% and comparable currency-neutral sales rose 3%.
- Gross profit increased to $1.035 billion (36.4% of sales) from $1.024 billion (35.3% of sales), with gross margin up 110 basis points.
- Total Adjusted Operating EBITDA was $578 million in both periods; Taste rose 12% and Pharma Solutions rose 15% on a reported basis, while Scent fell 14% and Food Ingredients rose 3%.
- Operating cash flow was $127 million versus $99 million a year earlier, while capital expenditures increased to $179 million from $118 million.
- Pharma Solutions disposal closed May 1, 2025 with gross cash proceeds of approximately $2.6 billion, with a portion used to repay the remaining $397 million under the 2026 Term Loan Facility.
- The company was in compliance with all debt covenants at March 31, 2025, with a net debt to credit adjusted EBITDA ratio of 3.93 to 1.0 and $711 million of available Revolving Credit Facility capacity.
03—One dollar
Follow one dollar
For each $1.00 of revenue in Q1 FY2025, International Flavors & Fragrances lost $0.36.
- Revenue$2.84B100.0%
- Cost of revenue−$1.81B63.6%
- Gross profit$1.03B36.4%
- Operating costs−$1.94B68.2%
- Operating income−$903.0M31.8%
- Interest, other & tax−$115.0M4.0%
- Net income−$1.02B35.8%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed May 6, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $2.84B$2.90B | −1.9% |
| Cost of Revenue | $1.81B$1.88B | −3.6% |
| Gross Profit | $1.03B$1.02B | +1.1% |
| R&D Expenses | $164.00M$166.00M | −1.2% |
| SG&A Expenses | $461.00M$490.00M | −5.9% |
| Operating Income | -$903.00M$199.00M | −553.8% |
| Interest Expense | $71.00M$83.00M | −14.5% |
| Net Income | -$1.02B$60.00M | −1796.7% |
| EPS (Basic) | $-3.98$0.23 | −1830.4% |
| EPS (Diluted) | $-3.98$0.23 | −1830.4% |
| Shares Outstanding (Basic) | 256.00M255.00M | +0.4% |
| Shares Outstanding (Diluted) | 256.00M256.00M | 0.0% |
05—Questions
Frequently Asked Questions
Why did IFF report a large net loss in the first quarter of 2025?
The net loss was driven primarily by a $1.153 billion impairment of goodwill related to the Food Ingredients reporting unit, which the company recognized after determining the unit's carrying amount exceeded its estimated fair value. The filing notes that the charge is mostly non-tax deductible, which contributed to an effective tax rate of (2.3)%.
How did IFF's sales and profitability perform excluding the goodwill impairment?
Net sales were $2.843 billion, down 2% on a reported basis, but up 2% on a currency-neutral basis and 3% on a comparable currency-neutral basis. Gross profit rose to $1.035 billion, and Total Segment Adjusted Operating EBITDA was flat at $578 million, with segment results varying widely.
What is the status of the planned divestitures?
The Pharma Solutions disposal group sale closed on May 1, 2025, with gross cash proceeds of approximately $2.6 billion, subject to preliminary closing adjustments. The Tobacco Flavoring business in North America sale closed April 1, 2025, for $20 million in gross proceeds. The Nitrocellulose business sale is expected to close in the second quarter of 2025.
How is IFF managing its debt and liquidity?
Cash and cash equivalents were $650 million including $37 million in assets held for sale, and total debt was $9.290 billion. The company was in compliance with all financial covenants, and it announced on May 2, 2025 tender offers for up to $1.8 billion of certain Senior Notes. The company also states its capital allocation strategy is primarily focused on debt repayment to maintain its investment grade rating.
What are the key risks and capital spending plans mentioned in the filing?
The filing discloses ongoing antitrust investigations related to the fragrance business by the European Commission, UK CMA, U.S. DOJ, and other authorities, with IFF stating it is unable to predict their outcome. Additional goodwill impairment could occur in the Taste reporting unit if key assumptions change. The company expects 2025 capital spending of approximately 6.5% of sales, up from 4.0% in 2024.
06—Continue